Regenera Appoints Dr. Deupree As Investigator

For immediate release

Perth, August 27: Regenera today announced that it has appointed two distinguished U.S. ophthalmologists to its clinical and medical advisory board.

Dr. Dana Deupree of The Macula Center, Palm Harbor, Florida, and Dr. David Boyer, Dr. Gholam Peyman and Dr. Don Sanders will be joining the team to assist in the investigation of Visagen^TM as a treatment to improve the effectiveness of the surgical procedure called vitrectomy.

Vitrectomy is a common form of eye surgery, often required as a result of diabetes-related eye diseases or other disorders that affect the retina and other sensitive areas at the back of the eye. Vitrectomy involves the removal of the vitreous (gel like substance) from the centre of the eye so that a surgeon can identify and remove loose blood particles and scar tissue that obscure the patient’s vision.

Over 150,000 vitrectomy operations are performed each year in the U.S. alone reflecting a sizeable potential market for Visagen^TM.

Regenera’s lead product, Visagen^TM, will be tested for use by Dr. Deupree to enhance his ability to visualise and clarify the vitreous fluid. This is a necessary step in the surgery as all of the fluid and loose particles must be removed to ensure the highest likelihood that the patient regains full vision.

CEO of Regenera Dr. William Ardrey said “The first indication that the clinical and medical advisory board will address is to prove the safety and efficacy of Visagen^TM for the visualization of the vitreous during vitrectomy. In this procedure, Visagen^TM is used prior to surgery as a visualization aide, and is washed out at the end of the procedure. It acts within the eye to illuminate or delineate the vitreous fluid.”

Dr Deupree is an ophthalmologist specializing in diseases of the vitreous and retina. His sub-specialty includes medical and surgical management of macular disorders, diabetic retinopathy, complex retinal detachments and trauma.

Dr Deupree is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. He also serves as Associate Professor at the University of South Florida. His current research interests include rheopheresis treatment for macular degeneration, in which he is a principal investigator in the current phase III clinical trial.

Official Regenera website